Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial

Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:01:10.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the removal of outdated results and the addition of new study dates and findings related to immune response and treatment efficacy.
    Difference
    9%
    Check dated 2025-05-22T03:38:27.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2025-05-07T19:30:44.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.7%
    Check dated 2025-04-30T14:19:43.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2025-04-23T12:25:49.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed descriptions of a clinical trial involving daratumumab and donor lymphocyte infusions for treating relapsed acute myeloid leukemia, while adding a new registry identifier and a revision number.
    Difference
    37%
    Check dated 2025-04-16T09:56:54.000Z thumbnail image

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.